Skip to main content
Enanta Pharmaceuticals has initiated a Phase II clinical trial for the treatment of community-acquired pneumonia in the United States and Canada for EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of community-acquired respiratory tract infections.

In the Pipeline

May 1, 2006

In The Pipeline

  • Enanta Pharmaceuticals has initiated a Phase II clinical trial for the treatment of community-acquired pneumonia in the United States and Canada for EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of community-acquired respiratory tract infections.
  • Nuvelo has been granted fast-track designation by the FDA for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion.
  • Genta has announced that the first patient has been entered into a new clinical study that will evaluate the bioactivity and safety of the company’s lead anticancer drug, oblimersen sodium (Genasense) injection, administered by intermittent subcutaneous injection.
  • EntreMed has initiated Phase II studies with MKC-1, a novel, orally active, small molecule cell cycle inhibitor with a unique mechanism of action. Patients with advanced or metastatic breast cancer who have failed conventional therapies are expected to be enrolled.
  • BioMarin Pharmaceutical has announced that the FDA has granted fast-track designation for sapropterin dihydrochloride (Phenoptin) for phenylketonuria.
  • Affymax has initiated a Phase II clinical trial of Hematide, a synthetic peptide-based erythropoiesis-stimulating agent, to treat anemia in cancer patients.
  • Schering-Plough reported that the FDA has granted fast designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment of chronic hepatitis C virus infection.